P1408: UPDATED RESULTS OF THE PHASE I BALLI‐01 TRIAL OF UCART22, AN ANTI‐CD22 ALLOGENEIC CAR‐T CELL PRODUCT, IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) CD22+ B‐CELL ACUTE LYMPHO... von Boissel, Nicolas, Chevallier, Patrice, Curran, Kevin, Schiller, Gary, Liu, Hongtau, Larson, Richard, Deangelo, Daniel J., Mear, Jean‐Baptiste, Grupp, Stephan, Baruchel, André, Konopleva, Marina, Lacroce, Alexandra, Roudet, Caroline, Korngold, Ana, Newhall, Katie, Laille, Eric, Lee, Daniel, Frattini, Mark, Jain, Nitin

Volltext

Updated Results of the Phase I BALLI-01 Trial of UCART22 Process 2 (P2), an Anti-CD22 Allogeneic CAR-T Cell Product Manufactured By Cellectis Biologics, in Patients with Relapsed o... von Jain, Nitin, Chevallier, Patrice, Liu, Hongtao, Schiller, Gary J., Méar, Jean-Baptiste, DeAngelo, Daniel J., Curran, Kevin J, Grupp, Stephan, Baruchel, Andre, Balsat, Marie, LaCroce, Alexandra, Roudet, Caroline, Korngold, Ana B., Newhall, Kathryn J., Laille, Eric, Lee, Daniel J., Frattini, Mark G., Larson, Richard A., Boissel, Nicolas

Volltext

Preliminary Results of Nathali-01: A First-in-Human Phase I/IIa Study of UCART20x22, a Dual Allogeneic CAR-T Cell Product Targeting CD20 and CD22, in Relapsed or Refractory (R/R) N... von Abramson, Jeremy S., Ramakrishnan, Aravind, Pierola, Ana Alfonso, Braunschweig, Ira, Cartron, Guillaume, Thieblemont, Catherine, Pérez-Simón, Jose A., Barba, Pere, Riedell, Peter A., Solano, Carlos, Gastinne, Thomas, LaCroce, Alexandra, Thomas, Denise, Poirot, Camille, Meadows, Sarah, Newhall, Kathryn J., Lee, Daniel J., Frattini, Mark G., Bachy, Emmanuel

Volltext